Pricing Log in Create free account

Fate Therapeutics, Inc. (FATE) vs Greenwich LifeSciences, Inc. (GLSI)

Fate Therapeutics, Inc. and Greenwich LifeSciences, Inc. are both Biotechnology companies. Fate Therapeutics, Inc. and Greenwich LifeSciences, Inc. are of similar size ($230.7M and $224.9M). Greenwich LifeSciences, Inc. has the higher net margin (0.00% vs −1,941.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Fate Therapeutics, Inc. leads on 6 and Greenwich LifeSciences, Inc. on 6.

Valuation

Metric FATE GLSI Biotechnology median
P/E n/m n/m 8.50
P/S 33.20 n/m 9.71
P/B 1.40 68.25 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 13.12 n/m 9.21
Earnings yield (58.66%) (10.58%) (33.15%)
Free cash flow yield (48.92%) (5.87%) (25.50%)

Profitability

Metric FATE GLSI Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (2,058.08%) 0.00% 0.00%
Net margin (1,941.09%) 0.00% 0.00%
Free cash flow margin (1,624.06%) 0.00% 0.00%
Return on equity (60.75%) (986.31%) (56.36%)
Return on assets (39.89%) (374.46%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric FATE GLSI Biotechnology median
Revenue growth (TTM) (23.36%) — 6.02%
EPS growth (last fiscal year) 29.88% (18.18%) 30.26%
Revenue growth, 5-year CAGR (26.71%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FATE GLSI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 1.54 4.72
Net debt to EBITDA 1.47 0.32 0.96

Dividend

Metric FATE GLSI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FATE GLSI Biotechnology median
Market cap 230.65m 224.87m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack